<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04694781</url>
  </required_header>
  <id_info>
    <org_study_id>LVGN6051-201</org_study_id>
    <nct_id>NCT04694781</nct_id>
  </id_info>
  <brief_title>Study of LVGN6051 (CD137 Agonist Antibody) in Advanced or Metastatic Malignancy</brief_title>
  <official_title>An Open Label, Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Pembrolizumab in Advanced or Metastatic Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lyvgen Biopharma Holdings Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lyvgen Biopharma Holdings Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study of LVGN6051-201 is designed to use a bridging dose escalation to quickly establish&#xD;
      the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDE) as well as&#xD;
      the recommended Phase 2 dose(s) (RP2D) of LVGN6051, both as a single agent (monotherapy) and&#xD;
      in combination with a fixed dose of anti-PD-1 antibody (Pembrolizumab) in the treatment of&#xD;
      advanced or metastatic malignancy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on the dose escalation results from the study of LVGN6051-101, a bridging dose&#xD;
      escalation (3+3) is used in study of LVGN6051-201. The traditional 3 + 3 dose escalation&#xD;
      algorithm to identify the MTD and/or RDE and RP2D of LVGN6051 as a single agent (monotherapy)&#xD;
      and in combination with pembrolizumab. The first stage of the study is the single agent dose&#xD;
      escalation and expansion phase (Part A). The second stage of the study is the combination&#xD;
      dose escalation and expansion phase (Part B). Patients will be considered evaluable for&#xD;
      safety and tolerability if they receive at least one dose of LVGN6051 or pembrolizumab at the&#xD;
      specified cohort dose. Patients in all parts of the trial will remain on therapy until&#xD;
      confirmed disease progression or for 2 years, whichever occurs first. However, patients who&#xD;
      are clinically unstable will discontinue following the initial assessment of disease&#xD;
      progression&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 10, 2021</start_date>
  <completion_date type="Anticipated">July 11, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 11, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-emergent adverse events (TEAEs) including determination of DLTs and serious AEs (SAEs)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Adverse events will be assessed, and severity will be assigned by using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MTD or RDE or RP2D</measure>
    <time_frame>up to 24 months</time_frame>
    <description>maximal tolerated dose, recommended dose for expansion or recommended phase 2 dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>up to 24 months</time_frame>
    <description>DCR will be documented as the proportion of patients with best overall response of CR, PR, or stable disease (SD). DCR per RECIST v1.1, iRECIST, and Cheson/Lugano criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter AUC</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Area under the serum concentration versus time curve (AUC) will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter Cmax</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Peak Plasma Concentration (Cmax) will be summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter t1/2</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Serum concentration half-life t1/2 will be summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADA to LVGN6051</measure>
    <time_frame>up to 24 months</time_frame>
    <description>The presence of ADA directed against LVGN6051 will be determined.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Monotherapy Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LVGN6051 monotherapy dose escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monotherapy Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LVGN6051 dose expansion cohorts</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination therapy dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LVGN6051 in combination with anti-PD-1 antibody pembrolizumab dose escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination therapy dose expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LVGN6051 in combination with anti-PD-1 antibody pembrolizumab dose expansion cohorts</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LVGN6051</intervention_name>
    <description>Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.</description>
    <arm_group_label>Combination therapy dose escalation</arm_group_label>
    <arm_group_label>Combination therapy dose expansion</arm_group_label>
    <arm_group_label>Monotherapy Dose Escalation</arm_group_label>
    <arm_group_label>Monotherapy Dose Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.</description>
    <arm_group_label>Combination therapy dose escalation</arm_group_label>
    <arm_group_label>Combination therapy dose expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females aged ≥ 18 years.&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent document.&#xD;
&#xD;
          -  Patients must have a histologically or cytologically confirmed metastatic or&#xD;
             unresectable malignancy.&#xD;
&#xD;
          -  Estimated life expectancy, in the judgment of the Investigator, of at least 90 days.&#xD;
&#xD;
          -  Adequate bone marrow, liver, and renal functions.&#xD;
&#xD;
          -  Men and women of childbearing potential must agree to take highly effective&#xD;
             contraceptive methods.&#xD;
&#xD;
          -  Patients should recover from all reversible AEs of previous anticancer therapies to&#xD;
             baseline.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receipt of CD137 and or PD-1 antibodies.&#xD;
&#xD;
          -  Receipt of systemic anticancer therapy within 5 half-lives of the first dose of study&#xD;
             treatment.&#xD;
&#xD;
          -  Known active CNS metastasis and/or carcinomatous meningitis.&#xD;
&#xD;
          -  Has received a live-virus vaccine within 30 days.&#xD;
&#xD;
          -  Has had a Grade ≥ 3 allergic reaction to treatment with a monoclonal antibody.&#xD;
&#xD;
          -  Abnormality of QT interval or syndrome.&#xD;
&#xD;
          -  Patients with history of Grade ≥ 3 immune-related AEs (irAEs) or irAE.&#xD;
&#xD;
          -  Patients who are receiving an immunologically-based treatment for any reason.&#xD;
&#xD;
          -  Active or chronic autoimmune disease that has required systemic treatment in the past&#xD;
             2 years or who are receiving systemic therapy for an autoimmune or inflammatory&#xD;
             disease.&#xD;
&#xD;
          -  Has a clinically significant cardiac condition, including unstable angina, acute&#xD;
             myocardial infarction within 6 months.&#xD;
&#xD;
          -  Has an active infection requiring intravenous (i.v.) anti-infectives within 14 days&#xD;
             before the first dose of study treatment.&#xD;
&#xD;
          -  Tested positive of HIV or HBV or HCV.&#xD;
&#xD;
          -  Female patients who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Any evidence of severe or uncontrolled systemic disease.&#xD;
&#xD;
          -  Has previously had a CAR-T therapy, or stem cell or bone marrow or solid organ&#xD;
             transplant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xin Luo</last_name>
    <role>Study Director</role>
    <affiliation>Lyvgen Biopharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>lynn Jiang, PhD</last_name>
    <phone>484-686-9652</phone>
    <email>lynn.jiang@lyvgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhen Zhou</last_name>
      <phone>8613611979382</phone>
      <email>jenniferzhou1116@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 16, 2020</study_first_submitted>
  <study_first_submitted_qc>January 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

